Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Timothy_Bertram
|
| gptkbp:clinicalTrialPhase |
Phase 3 clinical trial for REACT
|
| gptkbp:focusesOn |
regenerative medicine
chronic kidney disease |
| gptkbp:foundedYear |
2015
|
| gptkbp:headquartersLocation |
gptkb:Winston-Salem,_North_Carolina,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
ProKidney
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:product |
gptkb:REACT_(Renal_Autologous_Cell_Therapy)
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
gene therapy
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:PROK
|
| gptkbp:website |
https://www.prokidney.com/
|
| gptkbp:bfsParent |
gptkb:John_Maraganore
|
| gptkbp:bfsLayer |
6
|